Related Herbs
Botanicals connected by the same goals, effects, or research topics.
Herb Profile
Pueraria Mirifica
Pueraria mirifica
Pueraria Mirifica (Pueraria mirifica) carries a Grade C rating — limited evidence.
Last reviewed: •3 sources citedReport a correctionProfile-wide ·C Limited
Use extra caution — Avoid or use clinician supervision in pregnancy, breastfeeding, hormone sensitive cancers/conditions, unexplained vaginal bleeding, or concurrent estrogen/SERM/endocrine therapy. Details
- Evidence
- Limited Evidence
- Typical onset
- Varies by prep
- Safety rating
- High caution
- Best for
- Hormonal
- Avoid / review if
- Pregnancy/Breastfeeding Without Clinician Supervision, Known Allergy To The Plant/Family, Hormone Sensitive Conditions Without Clinician Review
At a glance
From this profile's structured data- Evidence
- Grade C
- Safety
- Avoid or use clinician supervision in pregnancy, breastfeeding, hormone-sensitive cancers/conditions, unexplained vaginal bleeding, or concurrent estrogen/SERM/endocrine therapy.
- Profile context
- hormonal
Next stepsWhere to go next — guides & comparisons
Continue reading
- If you want to browse more herbs → All herbs
Safety
Safety & Cautions
Avoid or use clinician supervision in pregnancy, breastfeeding, hormone sensitive cancers/conditions, unexplained vaginal bleeding, or concurrent estrogen/SERM/endocrine therapy.
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Interaction-AwareMedication or interaction context is explicitly noted.
- Hormonal Activity ContextHormone-adjacent wording is present and should be interpreted carefully.
- Anticoagulant CautionBleeding or anticoagulant-adjacent caution language is present.
- Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
Detailed safety fields
Pregnancy, breastfeeding, and contraindications
- Pregnancy/Breastfeeding Without Clinician Supervision
- Known Allergy To The Plant/Family
- Hormone Sensitive Conditions Without Clinician Review
- Potential Interaction Concern With Hormonal Therapies
- Use Clinician Review For High Dose Extracts Or Chronic Use.
Safety classifications
- Interaction-Aware: Medication or interaction context is explicitly noted.
- Hormonal Activity Context: Hormone-adjacent wording is present and should be interpreted carefully.
- Anticoagulant Caution: Bleeding or anticoagulant-adjacent caution language is present.
- Pregnancy/Breastfeeding Caution: Pregnancy or breastfeeding caution language is present.
Full safety note
- Avoid or use clinician supervision in pregnancy, breastfeeding, hormone sensitive cancers/conditions, unexplained vaginal bleeding, or concurrent estrogen/SERM/endocrine therapy.
Safety labels
- Interaction-Aware
- Hormonal Activity Context
- Anticoagulant Caution
- Pregnancy/Breastfeeding Caution
Evidence
Evidence Summary
Evidence lens
Read as directional context, not settled clinical proof.
LimitedLimited Evidence
Human clinical evidence: Not the primary signal
Mechanistic / preclinical: Mechanism mapped — Hormonal Signaling Context
Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.
Safety boundary: Safety note available — Avoid or use clinician supervision in pregnancy, breastfeeding, hormone sensitive cancers/conditions, unexplained vaginal bleeding, or concurrent estrogen/SERM/endocrine therapy.
This profile cites 3 human studies.
Study design details
Evidence Grade
Grade C: Limited Evidence
Evaluation of methodological rigor, population reach, and evidence alignment.
- Design Match
- Narrative review
- Risk of Bias
- High
- Consistency
- Not assessed
Strongest recorded design is a narrative review, drawn from 1 recorded study, none of which measured an outcome in people.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
Clinical Study Summaries (3)0 human evidence sources · 0 human trials · Participant totals not consistently reported · Consistency not yet classifiable
Filter by study class
Showing 3 of 3 studies.
What the evidence actually shows
This table contains 3 structured sources, including 0 human evidence sources; 0 are human trials. A reliable participant total cannot be calculated because sample size is not consistently structured in the cited sources. Source-to-conclusion relationships are not classified in this structured set, so consistency is not yet classifiable.
Profile-wide evidence grade: see the profile grade above · Confidence: not separately assigned
What would change our conclusion?
Larger, well-controlled human trials using comparable populations, doses, preparations, and clinically meaningful outcomes could materially strengthen or weaken this conclusion. Replication in a different population or a high-quality synthesis resolving current disagreement could also materially change confidence.
| Study | Design | N | Dose | Duration | Population | Outcome | Result & magnitude | Source |
|---|---|---|---|---|---|---|---|---|
Medical applications of phytoestrogens from the Thai herb Pueraria mirifica Malaivijitnond S et al. · Front Med · 2012 Background | Narrative review Summarizes selected literature without the full prespecified search and selection methods of a systematic review. | — | — | — | — | — | — | PubMed → |
Dietary Puerarin Supplementation Improves Immune Response and Antioxidant Capacity of Sows Cao S et al. · Antioxidants (Basel) · 2024 Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | — | PubMed → |
Inhibition of LPS-Induced Microglial Activation by the Ethyl Acetate Extract of Pueraria mirifica Jantaratnotai N et al. · Int J Environ Res Public Health · 2022 Background | Other / unclear The study design is not yet classified clearly enough to infer its place in the evidence hierarchy. | — | — | — | — | — | — | PubMed → |
Dosing & Timing
- No standardized dose
- Preparation specific; use standardized product label for Preparation varies by tradition and product form and require source backed dosage review before therapeutic claims.
How Pueraria Mirifica works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How Pueraria Mirifica Works
CompoundTarget / ReceptorMechanismEffect / Outcome
Mechanisms & biological pathways
Preclinical pathways. Proposed mechanisms from in vitro and animal research; these do not confirm clinical outcomes in humans.
- Hormonal Signaling Context
Active Compounds
Key constituents studied in Pueraria Mirifica, with full pharmacology and safety profiles.
Compare related active botanicals
Explore botanicals with similar chemistry, effects, or safety considerations in the Botanical Activity Atlas.
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Continue comparing
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?
Free safety checklist
Get the Pueraria Mirifica research notes
Evidence summaries, dosing context, and safety updates for this herb — straight to your inbox.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Botanical profile context
How to interpret Pueraria Mirifica
Pueraria Mirifica herb profile with evidence context, key research topics, source notes, safety context, and references presented in an evidence-first… Use this herb profile as a starting point for evidence review, not as a recommendation to start a new supplement. Botanical products can vary by plant part, extract ratio, standardization, dose, and contaminant testing, so two labels with the same common name may not behave the same way.
When reviewing Pueraria Mirifica, compare the traditional-use context against the human evidence, mechanism notes, and safety cautions. Pay special attention to pregnancy, breastfeeding, liver or kidney disease, blood-pressure effects, sedation, stimulation, anticoagulant use, antidepressants, and any prescription medication overlap.
For product decisions, prefer transparent labels, named extracts, clear serving sizes, and third-party quality testing. Avoid treating a long list of possible mechanisms as proof that an herb will solve a specific condition.